A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children with Friedreich's Ataxia

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The goal of this clinical trial is to evaluate the safety and tolerability of nomlabofusp (CTI-1601) in adolescents and children with Friedreich's ataxia (FRDA).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 17
Healthy Volunteers: f
View:

• Subject has genetically confirmed diagnosis of FRDA manifested by homozygous GAA repeat expansions, with repeat sizing (if available) included on the diagnosis report.

• Male or female subjects ≥ 2 to \< 18 years of age at screening.

• Subjects must weigh ≥ 10.0 kg.

• Subject must be able to traverse a distance of 25 feet with or without some assistive device (e.g., cane, walker, crutches, self-propelled wheelchair) and meet the following requirements:

‣ Be able to sit upright with thighs together and arms crossed without requiring support on more than 2 sides;

⁃ Be able to transfer from bed to chair independently or with assistance if, in the opinion of the investigator, the degree of physical disability does not result in undue risk to the subject while participating in the study; and

⁃ Perform basic age-appropriate daily care, such as feeding themselves and personal hygiene, with minimal assistance.

Locations
United States
Maryland
Uncommon Cures
RECRUITING
Chevy Chase
Contact Information
Primary
Tamanna Roshan Lal, MB ChB
troshanlal@UncommonCures.com
240-858-4938
Backup
Kerri Gallagher, RN, B
kgallagher@UncommonCures.com
240-858-4912
Time Frame
Start Date: 2024-12-06
Estimated Completion Date: 2025-08
Participants
Target number of participants: 30
Treatments
Experimental: Nomlabofusp
Subcutaneous injection of 0.8 mg/kg, with a maximum dose of 50 mg, once daily for 7 days
Placebo_comparator: Placebo
Subcutaneous injection once daily for 7 days
Sponsors
Leads: Larimar Therapeutics, Inc.

This content was sourced from clinicaltrials.gov